Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.…
Does Neurogene (NGNE) Have the Potential to Rally 203.28% as Wall Street Analysts Expect?
Neurogene (NASDAQ: NGNE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 131 employees.
The shares were at 22.15 USD on 20 November 2026, down 28.7% over 52 weeks. Its 52-week range is 15.93 USD to 43.66 USD: the price is 49.3% below the high and 39.0% above the low.
Its market capitalisation is 458.53M USD.
Neurogene reports return on equity of -34.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 352.17M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 77.63 USD is 250.5% above the current price. The next earnings report is expected on 24 March 2027.